Options Increase for CML Patients Failed by Existing Drugs
Options increase for CML patients failed by existing drugs
Filed under: inpatient drug treatment centers
It approved the drug ponatinib (Iclusig), which is effective in a significant number of patients with either disease. … will drastically improve the outcome of most patients with CML and PH+ALL who are resistant or intolerant to prior tyrosine kinase …
Read more on EurekAlert (press release)
Genentech and other big pharmaceutical companies cash in on HGH sales
Filed under: inpatient drug treatment centers
Sales of the average prescription drug rose just 12 percent in that same period. ——. EDITOR'S NOTE — Whether for … HGH also is sold directly without prescriptions, as new-age snake oil, to patients at anti-aging clinics that operate more like …
Read more on San Jose Mercury News
Rintatolimod for Chronic Fatigue Gets FDA Panel's 'No' Vote
Filed under: inpatient drug treatment centers
There are currently no approved drugs for the treatment of chronic fatigue syndrome, defined as a "complex, debilitating disorder of unknown etiology characterized by profound fatigue lasting for 6 or more consecutive months that is not improved by bed …
Read more on Medscape
Sarepta to have flu drug candidate tested by NIH
Filed under: inpatient drug treatment centers
Cambridge-based Sarepta Therapeutics Inc. (Nasdaq: SRPT), which is developing a gene-based treatment aimed at Duchenne muscular dystropy (DMD), is collaborating with the National Institutes of Health (NIH) for a Phase I study of a drug to treat …
Read more on Bizjournals.com (blog)